Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00866827
Other study ID # 20969
Secondary ID Unfunded, Retros
Status Completed
Phase
First received
Last updated
Start date December 2002
Est. completion date April 15, 2014

Study information

Verified date January 2019
Source University of Arkansas
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Controversy exists in the treatment of airway hemangiomas ranging from tracheotomy, various lasers, to open removal, none of which have proven to be a gold standard. Venous malformations of the airway are difficult to treat and also require laser therapy or open removal and often repeated treatments are required. Similarly airway lymphatic malformations can require multiple treatment modalities as well as multiple procedures and are infrequently eradicated when extensive. New uses for various lasers and differing treatment protocols are frequently developed. Review of the treatment modalities and efficacy of these methods is required. The goal of this research is to determine protocols for treatment of airway vascular malformation and to evaluate our results from treatment of these lesions.


Recruitment information / eligibility

Status Completed
Enrollment 75
Est. completion date April 15, 2014
Est. primary completion date April 15, 2014
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Airway Vascular Lesion

Exclusion Criteria:

- None at this time

Study Design


Intervention

Other:
Protocols for Treatment
Determine protocols for treatment of airway vascular malformation and to evaluate results from treatment of these lesions.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University of Arkansas
See also
  Status Clinical Trial Phase
Terminated NCT01212965 - Selenium in the Treatment of Complicated Lymphatic Malformations Phase 1
Completed NCT03427619 - OK432 (Picibanil) in the Treatment of Lymphatic Malformations Phase 2
Recruiting NCT05948943 - Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. Phase 2/Phase 3
Completed NCT02335242 - Sildenafil for the Treatment of Lymphatic Malformations Phase 2
Completed NCT00577213 - Diagnosis of Hemangiomas and Vascular Malformations N/A
Completed NCT00010452 - Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations Phase 2/Phase 3